Northeast Pharmaceutical Group Co., Ltd.

Northeast Pharmaceutical Group Co., Ltd. (NEPG) is a prominent player in the pharmaceutical manufacturing sector, listed on the Shenzhen Stock Exchange since 1996. The company operates across various segments, including chemical pharmaceuticals, pharmaceutical distribution, pharmaceutical engineering, and biopharmaceuticals. NEPG has established a comprehensive cluster that integrates both upstream and downstream activities within the pharmaceutical industry, providing a wide range of products and services. The company's diverse product portfolio includes ten major series, such as vitamins, anti-infectives, and reproductive system drugs, along with over 400 varieties of chemical APIs and formulation products. NEPG is recognized for its large-scale production capacity and strong cost control, allowing it to maintain a competitive edge in the global API market. Additionally, the company emphasizes environmental protection and sustainable practices in its operations. Its subsidiary, Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., focuses on advanced research in cell therapy, contributing to NEPG's robust R&D foundation and innovative product pipeline.

1.Brand Recognition As a traditional pharmaceutical enterprise, NorthEast Pharmaceutical Group Co., Ltd. enjoys high recognition within the industry. It holds solid market shares, particularly in products like Vitamin C, Levocarnitine, Piracetam, and Fosfomycin. Some of its products also occupy significant positions in the global market, with distinct advantages in quality and cost. 2.Large-Scale Production Capacity NorthEast Pharmaceutical Group Co., Ltd. possesses large-scale API production lines and strong cost control capabilities, granting it a price advantage in the global API market. Its products comply with both domestic and international quality standards, with several having obtained high-end international GMP certifications such as EDQM, Japan, South Korea, and Brazil, securing an important position in the international supply market. Through the integration and coordination of APIs and formulations, the company ensures formulation product quality and achieves comprehensive improvements in drug safety, efficacy, and stability. 3.Advantages in Comprehensive Environmental Protection NorthEast Pharmaceutical Group Co., Ltd. consistently adheres to the principle of "Safety first, environmental protection prioritized". It continuously increases investment in environmental protection facilities, clean production processes, and compliance management. Its supporting wastewater treatment installations enable separate treatment of high and low concentration streams. The company has built its own solid-liquid hazardous waste incineration unit to increase the self-sufficiency rate in hazardous waste disposal. For exhaust gases, it employs a combination of processes including RTO, CO (Catalytic Oxidation), activated carbon adsorption/desorption, scrubbing, and bag filtration for classified and synergistic treatment. The company actively promotes green and low-carbon transformation to achieve sustainable development. 4.Robust R&D Foundation NorthEast Pharmaceutical Group Co., Ltd. has established a Pharmaceutical Research Institute focused on drug R&D, possessing strong capabilities in efficient generic drug application submissions and bioequivalence (BE)/consistency evaluations. Furthermore, the company maintains long-term collaborations with renowned research institutions such as the Chinese Academy of Sciences and Shenyang Pharmaceutical University, accumulating rich technical expertise in API process optimization. 5.Cell Therapy Field Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., a holding subsidiary of NorthEast Pharmaceutical Group Co., Ltd., possesses unique advantages in the research of specific cellular immunotherapy technologies, product development, and clinical applications. These advantages include a distinctive technology platform, first-mover market positioning, a rich product pipeline, and the capability for rapid clinical application.